/ /

Robert J. Noecker, MD
Dr. Noecker, vice chair, University of Pittsburgh Medical Center Eye Center, and director, Glaucoma Service and associate professor of ophthalmology, University of Pittsburgh School of Medicine.
Managing glaucoma with surgical procedures (plural)
The advent of low-risk surgical options is moving glaucoma from a pharmaceutically managed disease to one controlled via a series of surgical procedures. The outcome appears to be highly beneficial for patients, says Robert J. Noecker, MD.
TCP gains traction as modality for glaucoma cases with good visual potential
A proprietary glaucoma device has changed current thinking about cyclophotocoagulation by offering another option in the glaucoma treatment algorithm and allowing earlier laser intervention when medical treatment comes up short.
Ocular sealant proves effective for routine, unexpected cases
In this physician perspective, Robert J. Noecker, MD, MBA, describes the results he has experienced since he has begun applying an ocular sealant as the last step of every filtering procedure.
Ideal patient profiles for ECP
Patient selection plays just as much of a role in the success of endoscopic cyclophotocoagulation as do surgical pearls. Identifying the proper patient population is a key for greater success.
Formula offers improved outcome
The experience of having a patient with early glaucoma is not uncommon.
Improved form of brimonidine has fewer contraindications
Brimonidine tartrate 0.15% (Alphagan P, Allergan) is a "new and improved" version of brimonidine 0.2% (Alphagan, Allergan). It continues to have an efficacy profile similar to the one ophthalmologists have grown used to with brimonidine 0.2%.
Purite May be Gentler Preservative for Lubrication Solutions
Almost all ophthalmic medications contain preservatives, which inhibit bacterial growth. The use of preservatives allows for the use of multidose bottles, which are the most cost-effective and user-friendly packaging for ophthalmic medications. However, some of the preservatives present in commonly used eye drops today have been shown to be disruptive to the cornea surface.1-5